The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.

• Blood Coagulation Disorders
• Acute Major Bleeding

• Biological: Beriplex® P/N
  Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
• Biological: Fresh frozen plasma
  Intravenous Infusion, dosage depending on baseline INR and body weight

• Beriplex® P/N: Experimental
  Intervention: Biological: Beriplex® P/N
• Fresh frozen plasma: Active Comparator
  Intervention: Biological: Fresh frozen plasma

Inclusion Criteria:

• Male and female subjects ≥ 18 years
• Subjects who have received anticoagulation therapy (warfarin, acenocoumarol or phenprocoumon)
• Subjects who have acute major bleeding, defined as one of the following: life-threatening or potentially life-threatening, acute bleeding associated with a fall in Hb level ≥ 2g/dL, bleeding requiring blood product transfusion
• INR ≥ 2 within 3 hours before start of study treatment
• Informed consent has been obtained

Exclusion Criteria:

• Expected survival of less than 3 days, or expected surgery in less than 1 day
• Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control the acute bleeding event
• For patients with ICH: Glasgow coma score < 9; intracerebral hematoma volume > 30cc as assessed by ABC/21; for subdural hematomas: maximum thickness ≥ 10 mm, midline shift ≥ 5 mm; for subarachnoid hemorrhage: any evidence of hydrocephalus; infratentorial ICH location; epidural hematomas; intraventricular extension of hemorrhage; modified Rankin score of >3 prior to ICH
• History of thrombotic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within 3 months of enrollment
• Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies
• Suspected or confirmed sepsis at time of enrollment
• Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into the study
• Large blood vessel rupture (e.g. in advanced cancer patient)
• Pre-existing progressive fatal disease with a life expectancy of less than 2 months
• Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia
• Treatment with any other investigational medicinal product within 30 days prior to inclusion into the study
• Presence or history of hypersensitivity to components of the study medication
• Pregnant or breast-feeding women
• Prior inclusion in this study or any other CSL Behring-sponsored Beriplex study